Scholar Rock Prices New SMA Therapy at 310000
Scholar Rock announced that its newly approved spinal muscular atrophy treatment will cost about 310000 annually. The drug Isembyld is the first therapy targeting muscle loss for the rare genetic disorder. Company executives report a steady launch pace.
Xurve View
Insights:
Xurve View
Scholar Rock Holding Corp priced its newly approved spinal muscular atrophy treatment at $310,000 annually per typical patient. The therapy is the first approved treatment targeting muscle loss in the disorder. Shares rose 5% following the announcement.
